vimarsana.com

Page 28 - பல்கலைக்கழகம் ஆஃப் புளோரிடா ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216

Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216 News provided by Share this article DALLAS, March 3, 2021 /PRNewswire/  Dialectic Therapeutics, Inc. (Dialectic ®), a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Targeted Degradation (APTaD™) technology. In pre-clinical studies supported through a Seed Award from the Cancer Prevention & Research Institute of Texas (CPRIT), DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy.

It hit me so hard : Utah ICU nurse battling COVID-19 released from hospital after double lung transplant

Q&A: UF Health virologist talks about variants and the future of the coronavirus

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.